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We had previously reported that splice isoforms of
tenascin-C containing the extra-domain C are virtually
absent in normal adult tissues but are highly abundant in
high-grade astrocytomas, with a prominent peri-vascular
pattern of expression. We now report that the extra-
domain C of tenascin-C is strongly expressed in the
majority of lung cancers, with a vascular and stromal
pattern of expression. Using antibody phage technology,
we have generated a human monoclonal antibody (G11),
with a dissociation constant KD = 4.2 nM for the
human domain C. The G11 antibody, expressed in scFv
and in mini-antibody (SIP) format, as well as a scFv-
interleukin-2 fusion protein, was then characterized in
quantitative biodistribution studies using mice grafted sub-
cutaneously with U87 gliomas, revealing a selective tumor
uptake, with tumor/blood ratios up to 11.8:1 at 24 h. A
radioiodinated preparation of SIP(G11) was also investig-
ated in a double tracer study using an orthotopic rat glioma
model, confirming the antibody’s ability to preferentially
localize at the tumor site, with tumor/brain ratios superior
to the ones observed with 18F-fluorodeoxyglucose. These
tumor-targeting properties, together with the strong
immunohistochemical staining of human tumor sections,
indicate that the G11 antibody may be used as a portable
targeting moiety for the selective delivery of imaging and
therapeutic agents to gliomas and lung tumors.
Keywords: angiogenesis/antibody phage display/human
monoclonal antibodies/tenascin-c/tumor targeting
Introduction
The targeted delivery of bioactive molecules (e.g. antibody
constant regions, cytokines, drugs, radionuclides, photosensit-
izers, pro-coagulant factors, etc.) to the tumor environment by
means of ligands specific to good-quality tumor-associated
antigens and endowed with suitable pharmacokinetic proper-
ties is a promising avenue for the therapy of disseminated
cancers (Carter, 2001; Neri and Bicknell, 2005).
Antigens, which are preferentially expressed in the modified
tumor extracellular matrix (ECM), are, in many respects, ideal
targets for tumor targeting applications (Brack et al., 2004;
Neri and Bicknell, 2005). ECM components are often more
abundant and more stable than antigens located on the surface
of tumor cells. Furthermore, they typically exhibit a low
shedding profile and are well accessible to agents (such as
antibody derivatives) coming from the bloodstream. Our group
has extensively demonstrated the tumor-targeting potential of
antibodies directed against components of the tumor ECM,
using as an example the L19 human monoclonal antibody
(Pini et al., 1998), specific to the EDB domain of fibronectin,
a marker of angiogenesis (Zardi et al., 1987; Kaczmarek et al.,
1994; Castellani et al., 1994, 2002). The L19 antibody was
shown to efficiently target tumor neo-vasculature and stromal
structures in animal models of cancer (Tarli et al., 1999; Viti
et al., 1999) and in patients with aggressive solid tumors
(Santimaria et al., 2003), and is now in clinical development
for cancer treatment as a radioiodinated antibody (Berndorff
et al., 2005), as a fusion protein with human interleukin-2
(Menrad and Menssen, 2005) and as a fusion protein with
human TNF (Borsi et al., 2003; Balza et al., 2006).
We have previously reported the over-expression of a splice
variant of another ECM component (tenascin-C containing the
extra-domain C) in high-grade astrocytomas, with a prominent
pattern of staining around tumor neo-vasculature. In contrast,
domain C was undetectable in normal human tissues by
immunohistochemistry and even at the level of Northern
blot analysis (Carnemolla et al., 1999). For practical applica-
tions, tumor-associated antigens and the corresponding anti-
bodies are particularly useful if they can be used to target at
least certain tumor classes with high incidence.
We report here that the extra-domain C is strongly expressed
in the majority of lung cancers, with a vascular and stromal
pattern of expression. Using state-of-the-art antibody phage
technology, we have generated a high-affinity human antibody
(‘G11’), which was shown to selectively target solid tumors in
rodents both as a recombinant antibody fragment and as fusion
protein with interleukin-2. These results pave the way for the
clinical development of the G11 antibody for the imaging and
therapy of gliomas and lung tumors.
Results
Isolation of the G11 antibody
We have recently described the construction of a large syn-
thetic human antibody library (termed ‘ETH2-GOLD’) and the
isolation of scFv(A12), a human antibody fragment specific
to domain C of tenascin-C, with a dissociation constant, KD, of
670 nM for the antigen (Silacci et al., 2005). In order to
improve the binding affinity of scFv(A12), an in vitro affinity
maturation procedure was performed by randomizing residues
in the CDR1 and CDR2 of the antibody heavy and light chains
according to a procedure previously described by our group
(Pini et al., 1998). In a first step a new antibody repertoire
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based on the sequence of the scFv(A12) was constructed by
combinatorially mutating positions 31, 32 and 33 of the VH
CDR1 and positions 52, 52a, 53 and 56 of the VH CDR2
(Table I). The residues chosen for randomization are found
to frequently contact the antigen in the known three-
dimensional structures of antibody–antigen complexes.
Moreover, in natural antibodies they are frequently found to
be diverse and to be subjected to somatic hypermutation
(Tomlinson et al., 1992). This repertoire containing 2 · 106
individual antibody clones was used for selections. Two rounds
of panning under stringent conditions were performed and
yielded several different scFv fragments specific to the C
domain of tenascin-C, whose monomeric binding affinity to
the antigen was characterized using BIAcore technology. The
antibody fragment scFv(E10) (Table I), which displayed the
lowest kinetic dissociation constant, was further characterized
by SDS–PAGE analysis, size exclusion chromatography and
by BIAcore analysis (Figure 1), which revealed a KD = 93 nM
for the human antigen (Table II). This corresponds to a factor
7 improvement, compared with the affinity of the parental
antibody fragment scFv(A12).
ScFv(E10) was further combinatorially mutated at positions
31, 31b and 32 in the VL CDR1 and at positions 50, 52 and 53
in the VL CDR2 (Table I). These residues were chosen on the
basis of the high sequence variability observed in natural
antibodies (Ignatovich et al., 1997). An antibody repertoire
containing 2.2 · 108 individual clones was obtained and used
for two rounds of panning under stringent conditions. The
clone scFv(G11) isolated from this library (Table I), which
showed the slowest kinetic dissociation from the antigen, was
purified and further characterized by SDS–PAGE analysis, by
size-exclusion chromatography and by BIAcore (Figure 1).
The monomeric dissociation constant KD of scFv(G11) is
equal to 4.2 nM for the human antigen (Table II), representing
an affinity improvement by a factor 22, compared with
scFv(E10), and a factor 160, compared with the parental anti-
body scFv(A12).
Immunohistochemistry with scFV(G11) on tumor sections
ScFv(G11) was extensively characterized by immunohisto-
chemistry on cryosections of human lung tumors and of normal
tissues. Figure 2 shows representative sections from different
types of lung cancer including: squamous cell carcinoma,
bronchial alveolar carcinoma, small cell carcinoma, large cell
carcinoma, pulmonary metastasis of renal cell carcinoma,
mesothelioma and lung adenocarcinoma. In all the lung tumor
sections studied, a moderate to very strong staining was
observed, with staining patterns ranging between a vascular-
type in certain tumors (e.g. squamous cell carcinoma) and a
predominantly stromal in others (e.g. lung adenocarcinoma).
The G11 antibody did not exhibit any detectable staining in
normal tissues (see representative examples in Figure 2), con-
firming the very restricted expression pattern of tenascin-C
isoforms containing the extra-domain C.
Cloning and expression of the G11 antibody in
different formats
We have previously reported that certain antibody formats
(e.g. mini-antibodies, cytokine fusions) may display certain
advantages for tumor-targeting applications in vivo (Borsi
et al., 2002; Carnemolla et al., 2002). For this reason, we
cloned scFv(G11) in small immunoprotein (SIP) format by
genetically fusing the scFv at the N-terminus of a human
eCH4 domain of the secretory isoform S2 of human IgE
(Figure 1; Borsi et al., 2002). This domain promotes the for-
mation of homodimers that are further stabilized by disulfide
bonds between the C-terminal cysteine residues, resulting in a
75 kDa bivalent miniantibody. This format has been shown to
be superior to IgG and to scFv for radioimmunotherapeutic
applications (Borsi et al., 2002; Berndorff et al., 2005).
Furthermore, we fused scFv(G11) with human interleukin-2
and produced the resulting fusion protein in mammalian cells
(Figure 1). In contrast to scFv(L19)-IL2, which can be pro-
duced as a non-covalent homodimer (Carnemolla et al., 2002;
Menrad and Menssen, 2005), scFv(G11)-IL2 proved to be
exclusively monomeric in physiological conditions (data not
shown).
Quantitative biodistribution studies in
tumor-bearing rodents
The in vivo tumor targeting properties of the different anti-
domain C of tenascin-C antibodies and antibody formats were
evaluated using radioiodinated protein preparations in both
mouse and rat tumor models. Biodistribution experiments
were performed in nude mice bearing U87 human glioblastoma
xenografts. This tumor model was shown to be strongly pos-
itive for the domain C-containing TN-C isoform in immuno-
histochemical analysis (Figure 2), with the G11 antibody
strongly staining the tumor vascular structures. 125I-labeled
antibodies [scFv(E10), scFv(G11) and scFv(G11)-IL2] were
injected intravenously; 24 h later, the animals were sacrificed,
the organs excised, weighted and radioactivity was counted.
While the antibody fragment scFv(E10), obtained prior to
the last affinity maturation step (Table I and Figure 1), failed to
preferentially localize to the tumor, all antibody formats
of G11 showed a selective accumulation at the tumor site
(Table III).
The tumor/blood ratios at 24 h for scFv(G11), SIP(G11) and
scFv(G11)-IL2 were 4.8, 5.6 and 11.8, respectively. Tumor/
organ ratios at 24 h ranged between 5 and 30 for scFv(G11)-
IL2, while being slightly lower for the other two formats.
In order to confirm the ability of the G11 antibody to target
tumors also in the orthotopic setting, we injected rats carrying
orthotopic C6 gliomas with a radioiodinated preparation of
SIP(G11) and 18F-fluorodeoxygluclose (FDG). Figure 3 shows
a side-by-side comparison of brain autoradiograms obtained
with the two tracers at 24 h and 15 min following injection,
respectively. The shorter imaging time used for FDG was
Table I. Sequences of the scFv fragments specific to the extra-domain C of
tenascin-C
scFv VH chain VL chain
31–33a 52–56a 95–100a 31–32a 50–53a 91–96a
A12 SYA SGSGGS HPPHRP SYY GKNN HGPRRP
E10 GSR NEEGGQ HPPHRP SYY GKNN HGPRRP
G11 GSR NEEGGQ HPPHRP LYY GKNN HGPRRP
Relevant amino acid positions of antibody clones isolated from the designed
synthetic libraries. Positions that are mutated in the primary antibody library are
underlined. Residues in E10 and G11, mutated during the affinity maturation
procedure, are in boldface. Single amino acid codes are used according to
standard IUPAC nomenclature.
aNumbering according to Tomlinson et al. (1992) and Williams et al. (1996).
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necessary in view of the faster clearance and shorter half-life of
this radiopharmaceutical. The autoradiographic analysis
clearly confirms the ability of SIP(G11) to localize to the
brain tumor, with a heterogenous accumulation of radioactivity
within the tumor mass, and its superior tumor to normal brain
ratio compared with FDG.
Discussion
We have generated a high-affinity antibody (G11) specific to
the extra-domain C of tenascin-C. We have demonstrated the
ability of different formats of this antibody (scFv fragment, SIP
and scFv-interleukin-2 fusion) to target tumors in vivo in two
different rodent models of cancer, with tumor to blood ratios at
24 h up to 11.8:1 and tumor to organ ratios up to 32:1. More-
over, the G11 antibody has allowed us to discover that the
extra-domain C of tenascin-C is strongly expressed in virtually
all types of lung cancer and mesothelioma, thus, opening tar-
geted therapeutic strategies for this class of neoplasias. Lung
cancer is the leading cause of cancer death in the world. With
the existing therapeutic efforts, patients with lung cancer still
have a poor prognosis and <15% live 5 years. This dismal
Fig. 1. Anti-domain C of tenascin-C antibodies. (A) Schematic representation of the different antibody formats and fusion protein used in this study. ScFv
fragment consisting of a variable heavy and a variable light chain connected by a peptide linker, the small immunoprotein (SIP) format, a disulfide-linked
homodimer and a scFv-IL2 fusion protein. (B) SDS–PAGE analysis of purified scFv(A12), scFv(E10), scFv(G11), SIP(G11) and scFv(G11)-IL2 under non-
reducing (NR) and reducing (R) conditions. (C, E, G) Size-exclusion chromatography profiles of the purified scFv(A12), scFv(E10) and scFv(G11), respectively.
The retention volume (ml) of the major peak corresponds to the monomeric form of the scFv fragments. (I) Size-exclusion chromatography profile of the purified
SIP(G11). The retention volume (ml) of the major peak corresponds to the disulfide-linked homodimer. (D, F, H, J) BIAcore analysis of the binding of
scFv(A12), scFv(E10), scFv(G11) and SIP(G11) to the extra-domain C of tenascin-C. Purified monomeric preparations of the scFv fragments and SIP(G11) were
injected at different concentrations and the kinetic constants were calculated with the BIAevaluation 3.1 software.
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statistic has changed minimally in the last 20 years, and, there-
fore, new therapeutic strategies are clearly needed.
In the recent past, other types of cancer have benefited
from the availability of monoclonal antibodies specific to
tumor-associated antigens, even when they would cover only a
small portion of the patients population [e.g. Herceptin
(Mokbel and Hassanally, 2001)]. Interestingly, G11 appears
to cover a much broader population and may, therefore, be
used for the construction of antibody-based pharmaceuticals,
with a substantial therapeutic potential in oncology.
A number of laboratories have compared the tumor-
targeting properties of affinity variants of the same monoclonal
antibody. For instance, the groups Marks/Adams/Weiner have
Table II.Affinities of the antibody fragments specific to the extra-domain C of
tenascin-C
Antibody kon (s
1M1) koff (s
1) KD (M)
scFv(A12) 5.4 · 104 6.0 · 102 6.7 · 107
scFv(E10) 1.0 · 105 9.3 · 103 9.3 · 108
scFv(G11) 6.7 · 104 2.9 · 104 4.2 · 109
The affinity measurements were obtained using a BIAcore 3000 instrument
(according to Neri et al., 1997). koff, kinetic dissociation constant; kon, kinetic
association constant; Kd, dissociation constant. The affinity of scFv(G11) to the
murine isoform of the extra-domain C of tenascin-C was also measured,Kd = 54
nM. Values are accurate to650%, on the basis of the precision of concentration
determinations.
Fig. 2. Representative findings of an immunohistochemical analysis performed on different types of human lung tumor sections obtained from surgically
resected tumors from patients, using the scFv(G11) as primary antibody (red staining, over the blue hematoxylin staining of cell nuclei). An intense vascular and/
or stromal pattern of staining was observed in virtually all surgical specimens analyzed in this study. In addition, the figure presents the strong vascular staining of
scFv(G11) of U87 human glioblastoma xenografts grown in nude mice, the model that was used for biodistribution analysis. In contrast, G11 staining was
undetectable in normal lung, normal breast and normal kidney sections. RCC = renal cell carcinoma.
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nicely shown that affinity maturation of a monomeric scFv
fragment specific to HER2-neu would correlate with improved
targeting until a threshold value (1 nM), after which targeting
performance did not appear to further increase (Adams et al.,
1998). Similarly, our group has previously demonstrated that
the high-affinity human antibody L19, specific to the EDB
domain of fibronectin, was capable of improved tumor target-
ing, compared with the parental antibody E1 (Viti et al., 1999).
In the present study, biodistribution data clearly show that the
high-affinity antibody fragment scFv(G11) targets tumors
more efficiently than the parental antibody scFv(E10), thus,
strengthening the concept that nanomolar binding antibodies
may be needed for efficient and selective tumor uptake. How-
ever, the use of bivalent antibody formats, with their enhanced
functional affinity, may improve the tumor-targeting perform-
ance even of antibodies with moderate affinity for the antigen
(Adams et al., 1998).
In our biodistribution analysis, scFv(G11)-IL2 exhibited
the best tumor-targeting performance. This may be due to
the vasoactive properties of the pro-inflammatory cytokine
IL2 (Epstein et al., 1995; Carnemolla et al., 2002). Our group
has recently developed scFv(L19)-IL2, a tumor-targeting
immunocytokine, which is currently in clinical trials. The
newly described scFv(G11)-IL2, which binds with high affinity
both to the human and to the murine domain C of tenascin-C,
appears to have a therapeutic potential for the treatment of
patients with lung cancer. It remains to be seen whether a
non-covalent homodimeric preparation of scFv(G11)-IL2,
obtained by shortening the polypeptide linker between VH
and VL (Holliger et al., 1993), may display superior tumor-
targeting properties compared with the monomeric format
described in this article.
The use of interleukins in cancer therapy has been hindered,
until now, by unacceptable toxicities already at relatively
low doses, thus, limiting dose escalation and the therapeutic
benefit for the patients. The use of human monoclonal antibody
fragments appears to be a logical avenue for the targeted
delivery of anti-cancer cytokines to neoplastic sites, with an
impressive therapeutic potential in animal models of cancer
(Becker et al., 1996; Penichet et al., 1997; Carnemolla et al.,
2002; Helguera et al., 2002; Menrad and Menssen, 2005). The
development of scFv(G11) and the discovery that this human
antibody strongly stains lung tumors paves the way for the
clinical development of novel immunocytokines to be
used either alone or in combination with chemotherapy
(Ebbinghaus et al., 2005) for the therapy of lung cancer. In
this respect, detailed pharmacological studies will be required
in order to learn about chemotherapeutic regimens (doses,
schedules), which are synergistic with scFv(G11)-IL2 and
other immunocytokines.
Table III. Biodistribution experiments of radiolabeled anti-domain C of tenascin-C antibodies in nude mice bearing U87 human glioblastoma xenografts
scFv(E10) scFv(G11) SIP(G11) scFv(G11)-IL2
Organs
Tumor 1 (0.07 6 0.02) 1 (0.71 6 0.03) 1 (0.85 6 0.07) 1 (0.48 6 0.03)
Blood 0.7 (0.11 6 0.01) 4.8 (0.15 6 0.02) 5.6 (0.15 6 0.02) 11.8 (0.04 6 0.01)
Liver 0.5 (0.15 6 0.02) 6.6 (0.11 6 0.01) 5.3 (0.17 6 0.02) 5.3 (0.09 6 0.01)
Kidney 0.1 (0.77 6 0.18) 1.4 (0.51 6 0.03) 3.7 (0.23 6 0.01) 4.8 (0.10 6 0.01)
Intestine 2.3 (0.03 6 0.01) 20 (0.04 6 0.01) 10.2 (0.08 6 0.01) 32.1 (0.02 6 0.01)
Spleen 1.8 (0.04 6 0.02) 21.8 (0.03 6 0.02) 6.5 (0.13 6 0.01) 8.3 (0.06 6 0.01)
Heart 1.5 (0.05 6 0.01) 12.6 (0.06 6 0.01) 14.9 (0.06 6 0.01) 29 (0.02 6 0.01)
Tumor/organ ratios, at 24 h after intravenous injection, are indicated in boldface. The numbers in brackets correspond to the percent antibody injected dose per gram
of tissue (%ID/g) 6 standard deviation.
Fig. 3. Double tracer study with 18F-Fluorodeoxyglucose (FDG) and 131I-SIP(G11) in C6 glioma bearing rats. Autoradiography of rat brain sections. SIP(G11)
was conjugated to 131I and injected (500–600 mCi) i.v. in the animals. After 24 h the animals were sacrificed. Because of the short half-life of
18F-Fluorodeoxyglucose (110 min), 1.2–1.7 mCi were injected just 15 min before sacrificing the animals. To quantitate the radioactive signal of the two tracers
two successive autoradiography were performed. First, brain sections were incubated 4 h to detect the 18F-Fluorodeoxyglucose signal. Then, the phosphoimager
screen was erased and the same sections incubated again 4 days, to reveal the 131I-SIP(G11) signal. The analyses of two different rats are compared here.
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Materials and methods
Selections of antibodies from the ETH-2 gold library
The domain C of tenascin-C was biotinylated with EZ-LinkTM
Sulfo-NHS-SS-Biotin (Pierce) according to manufacturer’s
instructions. The biotinylated antigen (final concentration
107 M) was incubated with 1012 phage particles in 1 ml
1% BSA for 40 min on a shaker at room temperature. The
phage–antigen complex was captured in previously avidin-
coated (first and third round) or streptavidin-coated (second
round) Maxisorp wells (Nunc, Germany). The phage–antigen
mix was distributed in eight wells and incubated for 20 min on
a shaker at RT. The wells were rinsed 10 times with phosphate-
buffered saline (PBS) 0.1% Tween-20 and 10 times with PBS.
Bound phage was eluted by incubation with 1 ml 50 mM
dithiotreitol for 5 min. The eluted phage was used to infect
exponentially growing Escherichia coli TG-1.
Construction of the affinity maturation libraries
In the first step of affinity maturation the scFv(A12) clone was
used as template for the construction of the library. Sequence
variability in the VH CDR1 and CDR2 of the library was
introduced by PCR using partially degenerate primers
DP47CDR1 for (50-CTGGAGCCTGGCGGACCCAGCTCAT-
MNNMNNMNNGCTAAAGGTGAATCCAGA-30) (all oligo-
nucleotide used in this work were purchased from Operon
Biotechnologies, Cologne, Germany) and DP47CDR2for
(50-GCCCTTCACGGAGTCTGCGTAGTATGTMNNACC-
ACCMNNMNNMNNAATAGCTGAGACCCACTCC-30), in
a process that generates random mutations at positions 31–33
of the VH CDR1 and at positions 52, 52a, 53 and 56 of the
VH CDR2. VHVL combinations were assembled in scFv
format by PCR assembly using the primers LMB3long
(50-CAGGAAACAGCTATGACCATGATTAC-30) and
fdseqlong (50-GACGTTAGTAAATGAATTTTCTGTATGA-
GG -30), using gel-purified VH and VL segments as
templates. The assembled VH–VL fragments were doubly
digested with NcoI/NotI and cloned into NcoI/NotI-digested
pHEN1 phagemid vector (Hoogenboom et al., 1991). The
resulting ligation product was electroporated into electro-
competent E.coli TG-1 cells according to (Viti et al., 2000),
giving rise to a library containing 2 · 106 individual antibody
clones.
In the construction of the second affinity maturation library
scFv(E10) clone was used as template. Sequence variability
in the VL CDR1 and CDR2 of the library was introduced
by PCR using partially degenerate primers DPL16CDR1for
(50-TCCTGGCTTCTGCTGGTACCAGCTTGCMNNMNN-
MNNTCTGAGGCTGTCTCCTTG -30), in a process that
generates random mutations at positions 31, 31b and 32 of the
VL CDR1 and at positions 50, 52, and 53 of the VL CDR2.
VH–VL combinations were assembled in scFv format by PCR
assembly LMB3long (50-CAGGAAACAGCTATGACCAT-
GATTAC-30) and fdseqlong (50-GACGTTAGTAAATGAAT-
TTTCTGTATGAGG-30), using gel-purified VH and VL
segments as templates. The assembled VH–VL fragments
were doubly digested with NcoI/NotI and cloned into NcoI/
NotI digested pHEN1 phagemid vector (Hoogenboom et al.,
1991). The resulting ligation product was electroporated into
electrocompetent E.coli TG-1 cells according to (Viti et al.,
2000), giving rise to a library containing 2.2 · 108 individual
antibody clones.
Selection of antibodies from the affinity maturation libraries
Biotinylated domain C of tenascin-C was used at a final
concentration of 108 M with 1012 transforming units (t.u.)
of phage antibodies in 1 ml 1% BSA for 40 min. The phage–
antigen complex was then captured using 5.3 · 107
streptavidin-coated magnetic beads (Dynal). The beads were
washed five times with 1 ml 0.1% Tween-20 in PBS (100 mM
NaCl, 50 mM phosphate, pH 7.4) followed by five times wash-
ing with 1 ml PBS. Bound phage was eluted with 1 ml 50 mM
dithiothreitol (Applichem, Germany) and amplified in E.coli
TG-1, using VCS-M13 (Stratagene) as helper phage. Phage
particles were purified from culture supernatant by PEG
precipitation (Viti et al., 2000).
Screening of supernatants by ELISA and by biacore
Induced supernatant of individual clones were screened
by ELISA as described by Viti et al. (2000) on high-bind
StreptaWell plates (Roche) coated with biotinylated antigen.
Bound antibody was detected by means of anti-peptide tag
antibodies, anti-myc tag antibody 9E10 (Marks et al., 1991),
followed by an anti-mouse immunoglobulin horse radish per-
oxidase (HRP) conjugate (SIGMA). The assay was developed
by a colorimetric reaction using BM-Blue POD soluble sub-
strate (Roche). Supernatants of ELISA positive clones were
further screened by surface plasmon resonance (SPR) real-time
interaction analysis on a high-density coated antigen chip,
using a BIAcore3000 instrument (BIAcore AB, Sweden).
Sequencing of scFV antibody genes
Antibodies were sequenced using Big Dye Terminator v1.1
Cycle Sequencing kit (Applied Biosystems) on an ABI PRISM
3130 Genetic analyzer. Templates for termination reactions
were either miniprep DNA or PCR products. Primers used for
sequencing were LMB3 long (50-CAGGAAACAGCTATGA-
CCATGATTAC-30; annealing upstream of scFv gene), fdseq
long (50-GACGTTAGTAAATGAATTTTCTGTATGAGG-30,
annealing downstream of scFv gene), and DP47CDR2ba
(50-ACATACTACGCAGACTCCGTGAAGGGC-30, anneal-
ing 100 bp upstream of VH CDR3).
Characterization of scFV antibodies
ScFv antibody fragments were expressed in E.coli TG-1 and
purified from culture supernatant and from periplasmic
preparations by affinity chromatography, using either protein
A sepharose (Amersham Biosciences) or antigen-coupled
sepharose obtained by coupling recombinant antigen to
CNBr-activated sepharose (Amersham Biosciences). Purified
antibodies were analyzed by size-exclusion chromatography
on superdex 75 HR10/30 columns (Amersham Biosciences),
peaks representing monomeric fractions were collected and
used for affinity measurements by BIAcore on a low-density
coated antigen chip.
Immunohistochemistry on frozen tissue sections
Sections of 8–12 mm thickness were treated with ice-cold
acetone, rehydrated in TBS (50 mM Tris, 100 mM NaCl,
pH 7.4) and blocked with 20% fetal bovine serum (Invitrogen).
Affinity-purified scFv fragments (final concentration
2–10 mg/ml) carrying an myc-tag were added onto the sections,
together with secondary antibody was monoclonal anti-
myc 9E10 antibody (5 mg/ml). Bound antibodies were
detected with rabbit anti-mouse immunoglobulins antibody
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(Dakocytomation, Denmark) followed by mouse monoclonal
alkaline phosphatase–antialkaline phosphatase complex
(APAAP; Dakocytomation, Denmark). Fast Red (Sigma)
was used as phosphatase substrate, and sections were counter-
stained with Gill’s hematoxilin No2 (Sigma).
Cloning, expression and purification of SIP(G11)
The SIP secretion sequence, which is required for secretion
into the extracellular medium, was amplified from the con-
struct SIP(L19)-pcDNA3.1 (Borsi et al., 2002) using primers
23paba (50-CTGAAGCTTGTCGACCATGGGCTGGAGCC-30)
and 29pafo (50-CAGCTGCACCT CCGAGTGCACACCTGT-
GGAGAG-30). The human eCH4 domain was amplified from
the same construct using primers 34paba (50-CTGACCGTCC-
TAGGCTCCGGAGGCTCTGGGGCCCCGCGTGCT-30) and
28pafo (50-CTGGAATTCGAGCTCGGTACCTAGCAGCCA-
CCC-30). ScFv was amplified with 30paba (50-GGTGTGCAC-
TCGGAGGTGCAGCTGTTGGAGTCT-30) and 33pafo
(50-CCCAGAGCCTCCGGAGCCTAGGACGGTCAGCTTG-
GTCCCTCC-30). The resulting PCR fragments were gel puri-
fied, assembled by PCR and cloned into vector pcDNA3.1
(Invitrogen) by means of HindIII and EcoRI digestion. The
constructs were used to transfect HEK293 cells using FuGENE
6 transfection reagent (Roche). Transfected HEK293 cells
were grown in DMEM (Invitrogen) supplemented with 10%
FBS (Invitrogen) and selected using 500 mg/ml of Geneticin
(G418, Calbiochem). Monoclonal cultures were obtained by
limited dilution. SIP(G11) was purified from supernatant by
affinity chromatography using antigen-coated sepharose resin.
The purified protein was analyzed by SDS–PAGE, size-
exclusion chromatography using a superdex 200 HR 10/30
column and by BIAcore.
Cloning, expression and purification of scFV(G11)-il2
Cloning of the scFv(G11)–IL2 fusion protein was performed as
previously described for the scFv(L19)–IL2 fusion protein
(Carnemolla et al., 2002). IL2 was obtained by digestion of
the scFv(L19)–IL2 containing pcDNA3.1 vector using the
restriction enzymes EcoRI and BamHI. The scFv(G11) was
amplified by PCR using the primers PG39 (50-AAACTTA-
AGCTTGTCGACCATGGG-30) and PG40 (50-ATAGAATT-
CGCCTAGGACGGTCAGCTTGG-30). The amplified DNA
was digested with HindIII and EcoRI. The gel-purified DNA
fragments [scFv(G11) and IL2] were ligated into the HindIII/
BamHI double-digested pcDNA3.1 vector. The constructs
were used to transfect CHO cells using FuGENE 6 transfection
reagent (Roche). Transfected CHO cells were grown in RPMI
1640 (Invitrogen) supplemented with 10% FBS (Invitrogen),
4 mM L-Glutamine (Invitrogen) and selected using 500 mg/ml
of Geneticin (G418, Calbiochem). Monoclonal cultures were
obtained by limited dilution. scFv(G11)–IL2 was purified from
supernatant by affinity chromatography using antigen-coated
sepharose resin. The purified protein was analyzed by
SDS–PAGE and size-exclusion chromatography using a super-
dex 200 HR 10/30 column.
Biodistribution in U87 human glioblastoma model
U87 human glioblastoma cells (HTB-14, ATCC) were cultured
in MEM (Minimal Eagles Medium, Invitrogen) supplemented
with 10% FBS, 2 mM L-glutamine (Invitrogen), 1 mM sodium
pyruvate (Invitrogen) and antibiotics at 37C in an atmosphere
of 5% CO2. 3 · 106 U87 human glioblastoma cells were
injected subcutaneously into the right flank of 6–8-week-old
female Balb-C nu/nu mice (Charles River Laboratories). The
tumors were allowed to grow for 20–25 days. By then, tumors
reached a size of typically 200 mg and were used for biod-
istribution studies.
The in vivo targeting performance of the different antibody
formats was evaluated by biodistribution analysis as described
by (Tarli et al., 1999). Briefly, the different purified antibody
formats were radioactively labeled with 125I using the Iodogen
method (Fraker and Speck, 1978; Salacinski et al., 1981) and
injected i.v. into U87 human glioblastoma xenograft bearing
nude mice. About 4 mg of each protein was injected. Animals
were sacrificed 24 h after injection. Organs were excised,
weighed and the radioactivity was counted. Targeting results
of representative organs are expressed as percentage of
injected dose per gram of tissue (%ID/g).
Double tracer study in an orthotopic rat glioma model
0.5 mg of SIP(G11) was coupled to 131I according to the
chloramine-T method (Visser et al., 2001). The radiolabeled
antibody was then purified from the free iodine by gel filtra-
tion on a PD-10 desalting column (Amersham Biosciences).
0.5–0.6 mCi of 131I-SIP(G11) was injected i.v. in rats bearing
an orthotopic brain tumor, C6 malignant glioma (Sherburn
et al., 1999). To assess the targeting performance of the iod-
inated antibody G11 autoradiography analysis of brain sections
was performed 24 h after injection. For comparison the animals
were also injected with 1.2–1.7 mCi of 18F-Fluorodeoxyglu-
cose (FDG) 15 min before being sacrificed. To quantitate the
radioactive signal of the two tracers two successive autoradio-
graphy were performed. First, brain sections were incubated
4 h to detect the 18F-Fluorodeoxyglucose signal. Then, the
phosphoimager screen was erased and the same sections incub-
ated again 4 days, to reveal the 131I-SIP(G11) signal.
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